GlassScriptPhysician profile
Ana Migone
NPI 1790753341
$2,988.71
in general payments reported to CMS, 2019-2025
30 companies · $317 in 2025
The $317 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $531 · 2020: $139 · 2021: $379 · 2022: $285 · 2023: $402 · 2024: $935 · 2025: $317.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,385 · Education: $269.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,384.62 |
| Education | $268.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $576.63 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $528.81 | 2021-2025 | |
| Astellas Pharma US INC | $438.92 | 2019-2024 | |
| Pfizer INC. | $182.80 | 2019-2022 | |
| Glaxosmithkline, LLC. | $159.92 | 2019-2025 | Shingrix, Arexvy, Bexsero |
| Dexcom, INC. | $157.34 | 2021-2025 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $144.66 | 2020-2024 | Breztri, Airsupra, Farxiga |
| Amgen INC. | $117.49 | 2019-2024 | Repatha, Otezla |
| Novartis Pharmaceuticals Corporation | $108.13 | 2023-2024 | |
| Lilly USA, LLC | $95.88 | 2019-2025 | Kisunla, Jardiance, Zepbound |
| Aimmune Therapeutics, INC. | $56.76 | 2024 | |
| Allergan, INC. | $46.17 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $45.90 | 2024 | Fanapt |
| Acadia Pharmaceuticals INC | $34.72 | 2020-2025 | Daybue |
| Sunovion Pharmaceuticals INC. | $27.76 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $27.44 | 2024 | |
| Boston Scientific Corporation | $22.85 | 2025 | Watchman Access System |
| Nestle Healthcare Nutrition INC. | $22.53 | 2021 | |
| Merck Sharp & Dohme LLC | $21.21 | 2024 | Vaxelis, Gardasil 9, Capvaxive |
| Mylan Specialty L.P. | $19.26 | 2023 | Yupelri |
| Mayne Pharma Commercial LLC | $19.26 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $19.07 | 2022 | |
| Janssen Pharmaceuticals, INC | $17.05 | 2019 | |
| Corcept Therapeutics | $16.88 | 2023 | Korlym |
| Ge Healthcare | $16.48 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.60 | 2021 | |
| Exact Sciences Corporation | $13.46 | 2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.10 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $12.92 | 2023 | Rexulti |
| Ucb, INC. | $11.71 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ana Migone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.